• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States
ConclusionElderly AML patients had more comorbidities and higher rates of complications compared to non-cancer controls. Considering comorbidities and complications in elderly AML patients may improve clinical decision-making.
Source: Clinical Lymphoma Myeloma and Leukemia - April 30, 2019 Category: Cancer & Oncology Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Conclusions Patients with AML have an elevated risk of CVA compared to all inpatients and mortality in this population is high. Better characterization of risk factors of stroke in this vulnerable population is still needed. Teaser Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke i...
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up
Conclusion The incidence of CVEs and the frequency of asymptomatic PAD in this population was low, and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes might have contributed to the findings. Further prospective and adequately powered studies are needed to explore the effect of the cardiovascular risk profile on CVEs in CML patients taking nilotinib. Micro-Abstract The present study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long-term exposure to ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 11, 2017 Category: Cancer & Oncology Source Type: research

Cardiovascular Events after Exposure to Nilotinib in Chronic Myeloid Leukemia: Long Term Follow up
Conclusion The incidence of CVEs and frequency of asymptomatic PAD in this population was low and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes, might have contributed to the result. Further prospective and adequately powered studies are needed to explore the effect of cardiovascular risk profile on CVEs in CML patients on Nilotinib. Teaser This study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long term exposure to Nilotinib. By considering the...
Source: Clinical Lymphoma Myeloma and Leukemia - July 15, 2017 Category: Cancer & Oncology Source Type: research

Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States
Conclusion The increased risk of CVD observed in this real-world analysis of CML patients underscores the importance of current NCCN® recommendations to consider CV risk when selecting TKIs. Teaser Guidelines recommend that comorbidities, including CVD, be considered when selecting TKIs for the treatment of CML. An increased risk of CVD and its risk factors in CML patients treated by community-based US oncologists was identified in a real-world analysis of an EMR database (N=1,639). These results underscore the importance of current NCCN® recommendations to consider CV risk when selecting TKIs.
Source: Clinical Lymphoma Myeloma and Leukemia - June 20, 2017 Category: Cancer & Oncology Source Type: research

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data
Conclusion Elderly patients with CML had greater mortality and greater rates of MI, stroke, PE, and PAD than did noncancer patients. The event rates were not elevated among the TKI-treated (primary imatinib) patients, suggesting that the VE risk in these patients with CML was driven primarily by the underlying factors associated with CML. Micro-Abstract Tyrosine-kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can be associated with vascular events (VEs). We examined the event rates and mortality among elderly patients with and without CML using linked cancer registry and Medicare claims data from 2003 t...
Source: Clinical Lymphoma Myeloma and Leukemia - March 21, 2016 Category: Cancer & Oncology Source Type: research

Mortality and Vascular Events Among Elderly Patients with Chronic Myeloid Leukemia (CML): A Retrospective Analysis of Linked Seer-Medicare Data
Conclusions Elderly CML patients had higher mortality and higher rates of MI, stroke, PE and PAD than non-cancer patients. Event rates were not elevated among TKI-treated (primary imatinib) patients, suggesting that VE risk in these CML patients was driven primarily by underlying factors associated with CML. Teaser TKI treatment of CML may be associated with vascular events (VE). We examined event rates and mortality among elderly CML and non-cancer patients using linked cancer registry and Medicare claims data, 2003-2010. CML patients had higher mortality and VE rates. Rates were not elevated among TKI (primarily imatinib...
Source: Clinical Lymphoma Myeloma and Leukemia - February 7, 2016 Category: Cancer & Oncology Source Type: research

Central Nervous System Complications and Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
Conclusions The occurrence of CNSCs after ALLO-HSCT was associated with reduced survival. Identifying patients at risk, monitoring, early detection and management of CNSCs post ALLO-HSCT is needed to improve outcomes. Teaser This retrospective study of 351 patients, who have undergone allogeneic hematopoietic stem cell transplantation between 2002 and 2011 at the University of Nebraska Medical Center, demonstrated 12% incidence of central nervous system complications. The most common complications included posterior reversible encephalopathy syndrome (40%), stroke or transient ischemic attack (24%), seizures (20%), and inf...
Source: Clinical Lymphoma Myeloma and Leukemia - June 30, 2015 Category: Cancer & Oncology Source Type: research